{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Part 2 (evaluation of safety of blinded BCX7353)', 'Part 2 of the study will start upon administration of study drug dispensed at the Week 24 visit.', 'Subjects in Groups 1 and 2 will continue to receive the same BCX7353 dose to which they were', 'randomized in Part 1 of the study in a blinded manner. Subjects randomized to Group 3 will', 'undergo a second randomization in a 1:1 ratio to receive either a 110 or 150 mg QD dose of', 'BCX7353 in a blinded manner beginning at the Week 24 visit (see Figure 1). The active dose a', 'subject receives in Part 2 will be blinded for all subjects; subjects will be informed that they will', 'receive an active dose of BCX7353 in Part 2. Once Part 1 results are available, all subjects in', 'Part 2 may be moved to a single dose of BCX7353, based on the data from Part 1.', 'Study visits in Part 2 will occur during Weeks 26, 28, 32, 36, 48, and 52, with telephone contact', 'at Weeks 40 and 44. Subjects will continue to document all angioedema events that occur while', 'on study drug, as well as compliance with the study drug, in their e-diary and will have regular', 'visits to assess safety and tolerability; investigator confirmation of angioedema events will', 'continue to be required for Part 2. Interim safety analyses will be conducted while Parts 2 and 3', 'are ongoing to support regulatory filings.', 'Part 3 (up to a 52-week evaluation of the safety of open-label BCX7353 150 mg QD)', 'Part 3 of the study will start with the administration of the study drug dispensed at the Week 52', 'visit. Based on the safety profile and efficacy of the 150 mg dose in Part 1 of the similarly', 'designed Study BCX7353-302, all subjects in the current study receiving 110 mg QD will be', 'transitioned to open-label 150 mg QD at the Week 52 visit.', 'Study visits in Part 3 will occur during Week 60 and approximately every 12 weeks thereafter,', 'for a study duration of up to 104 weeks, until another mechanism is available to provide drug to', 'the subject (eg, market access), or until the sponsor discontinues development of the product for', 'the prevention of angioedema attacks, whichever comes first. Telephone contact will occur at', 'Weeks 56, 64, 68, 76, 80, 88, 92, and 100.', 'Subjects will continue to document all angioedema events that occur in their diary throughout', 'Part 3 and will have regular visits to assess safety and tolerability. However, subjects will not', 'be', 'required to document compliance with the study drug. In addition, investigator and expert', 'confirmation of angioedema events will not be required in Part 3. All angioedema events', 'recorded by the subjects will be reviewed and confirmed or rejected according to a set of', 'pre-defined rules prior to inclusion in effectiveness analyses. These rules will be outlined in the', 'Statistical Analysis Plan (SAP).', 'Post-Marketing Study', 'Once BCX7353 receives marketing authorization in Japan, this study will be transitioned to a', 'post-marketing study. Each subject remaining on study may continue to receive access to', 'BCX7353 through Week 104 or until such time as BCX7353 is commercially available at his or', 'her site, whichever occurs first, unless the subject discontinues his or her participation in the', 'study. During this period, BCX7353 will be administered at the dose regimen that is approved in', 'Japan. In the event that BCX7353 is not commercially available when the first and each', 'subsequent subject at each site reaches Week 104, then the treatment period will be extended', 'with additional telephone contacts conducted at 4-week intervals (Weeks 108, 112, etc.) and', 'clinic visits completed at 12-week intervals (Week 116, etc.) to allow each subject to continue', '39']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'treatment with BCX7353 until commercially available, unless the subject discontinues his or her', 'participation in the study. Once BCX7353 is commercially available at each site, an end-of-study', '(EOS) visit will be scheduled for each subject to complete his or her participation in the study', 'and transition to commercial drug product. Subjects will not have to wait for their next scheduled', 'clinic visit to complete the EOS visit. Subjects may not continue on study for more than', '3 months after National Health Insurance (NHI) price listing in Japan. Subjects who choose not', 'to continue their participation in the study at any time will be asked to complete an early', 'termination visit within 3 weeks (+ 1 week) after their last dose of BCX7353.', '7.1.', 'Enppoints', '7.1.1.', 'Part 1 Primary Efficacy Endpoint', 'The primary efficacy endpoint of the study is as follows:', 'The rate of expert-confirmed angioedema events during dosing in the entire 24-week', 'treatment period (Days 1 to 168)', '7.1.2.', 'Part 1 Secondary Efficacy Enppoints', 'Secondary efficacy endpoints are as follows:', 'Change from baseline in AE-QoL at Week 24 (total score)', 'Number and proportion of days with angioedema symptoms through 24 weeks', 'Rate of expert-confirmed angioedema events during dosing in the effective treatment', 'period (beginning on Day 8 through 24 weeks)', '7.1.3.', 'Part 1 Exploratory Efficacy Enppoints', 'Number and proportion of subjects with no angioedema events over 24 weeks', 'Use of medications to treat angioedema events over 24 weeks', 'The proportion of responders to study drug, separately defined as at least a 50%,', '70%, or 90% relative reduction in the rate of expert-confirmed angioedema events', 'during treatment compared with the baseline expert-confirmed angioedema event rate', '7.1.4.', 'Part 1 Safety Enppoints', 'Number and proportion of subjects with a TEAE', 'Number and proportion of subjects who discontinue due to a TEAE', 'Number and proportion of subjects who experience a TESAE', 'Number and proportion of subjects who experience a Grade 3 or 4 TEAE', 'Number and proportion of subjects who experience a treatment-emergent Grade 3 or', '4 laboratory abnormality', '7.1.5.', 'Part 1 Health Outcome Enppoints', 'EuroQoL 5-dimensional, 5-level questionnaire (EQ-5D-5L) scores', '40']\n\n###\n\n", "completion": "END"}